Advertisement

Effects of the Interleukin-1 Cytokine Family on Bone

Conference paper

Abstract

Cytokines are major regulators of bone homeostasis and influence the function of both osteoblasts and osteoclasts. For instance, receptor activator of NF-kB ligand (RANKL) is a member of the tumor necrosis factor (TNF) family and an essential mediator of osteoclastogenesis. Apart from RANKL, proinflammatory cytokines modulate osteoclast differentiation, amongst them TNF-α is a potent stimulator of osteoclastogenesis. Other proinflammatory cytokines like IL-17 and IL-11 are also stimulators of bone resorption by inducing osteoclast differentiation, whereas others such as interferon-(IFN)-γ and IL-12 suppress osteoclastogenesis and balance enhanced bone resorption. In this chapter, we focus on the IL-1 of cytokine family and summarize their role on bone homeostasis. Members of the IL-1 cytokine family are involved in multiple cellular functions including the innate and adaptive immune system. They are key mediators of inflammation and govern the complex processes of cell trafficking, cytokine and matrix enzyme release, fever responses, and metabolic changes during inflammatory disease.

Keywords

Osteoclast Differentiation Bone Homeostasis Fever Response Systemic Bone Loss Induce Osteoclast Differentiation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Gowen M et al (1983) An interleukin 1 like factor stimulates bone resorption in vitro. Nature 306(5941):378–380PubMedCrossRefGoogle Scholar
  2. 2.
    Boyce BF et al (1989) Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 125(3):1142–1150PubMedCrossRefGoogle Scholar
  3. 3.
    Jimi E et al (1999) Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res 247(1):84–93PubMedCrossRefGoogle Scholar
  4. 4.
    Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL (2005) IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115:282–290PubMedGoogle Scholar
  5. 5.
    Zwerina J et al (2007) TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 104(28):11742–11747PubMedCrossRefGoogle Scholar
  6. 6.
    Polzer K, Joosten L, Gasser J et al (2010) Interleukin-1 is essential for systemic inflammatory bone loss. Ann Rheum Dis 69(1):284–290PubMedCrossRefGoogle Scholar
  7. 7.
    Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, Gravallese E, Mathis D, Benoist C (2002) Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med 196(1):77–85PubMedCrossRefGoogle Scholar
  8. 8.
    Aoki Y, Ichimura S, Kikuchi T, Yoshihara Y, Kogawa M, Tada N, Nemoto K et al (2005) Overexpression of the human Interleukin 1a gene causes osteopenia in mice. J Rheumatol 32:320–324PubMedGoogle Scholar
  9. 9.
    Okamura H et al (1995) Cloning of a new cyokine that induces IFN-g production by T cells. Nature 378:88–91PubMedCrossRefGoogle Scholar
  10. 10.
    Ragatt LJ et al (2008) Interleukin-18 is regulated by parathyroid hormone and is required for its bone anabolic actions. J Biol Chem 283:6790–6798CrossRefGoogle Scholar
  11. 11.
    Makiishi-Shimobayashi C, Tsujimura T, Iwasaki T, Yamada N, Sugihara A, Okamura H, Hayashi S, Terada N (2001) Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. Biochem Biophys Res Commun 281(2):361–366PubMedCrossRefGoogle Scholar
  12. 12.
    Udagawa N et al (1997) Interleukin 18 (interferon-g-inducing factors) is produced by osteoblastst and acts via granulocyte/macrophage colony stimulating factor and not via interferon-g to inhibit osteoclast formation. J Exp Med 185:1005–1012PubMedCrossRefGoogle Scholar
  13. 13.
    Horwood NJ et al (1998) Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest 101(3):595–603PubMedCrossRefGoogle Scholar
  14. 14.
    Schmitz J et al (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479–490PubMedCrossRefGoogle Scholar
  15. 15.
    Liew FY, Pitman NI, McInnes IB (2010) Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 10:103–110PubMedCrossRefGoogle Scholar
  16. 16.
    Schulze J, Bickert T, Beil FT et al (2011) Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J Bone Miner Res 26:704–717PubMedCrossRefGoogle Scholar
  17. 17.
    Zaiss MM, Kurowska-Stolarska M, Böhm C et al (2011) Interleukin (IL)-33 shifts the balance from osteoclast to alternatively- activated macrophage differentiation and protects from TNFa-mediated bone loss. J Immunol 186(11):6097–6105PubMedCrossRefGoogle Scholar
  18. 18.
    Mun SH et al (2010) Interleukin-33 stimulates formation of functional osteoclasts from human CD14(+) monocytes. Cell Mol Life Sci 67(22):3883–3892PubMedCrossRefGoogle Scholar
  19. 19.
    Saidi S et al (2011) IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling. Cytokine 53:347–354PubMedCrossRefGoogle Scholar

Copyright information

© Springer New York 2013

Authors and Affiliations

  1. 1.Department of Internal Medicine 3University of Erlangen-NurembergErlangenGermany

Personalised recommendations